Ramipril Capsule
Product Images NDC 51655-296

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 51655-296). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 296 52)

Label (51655 296 52)
This is a description of Ramipril capsules, USP with a strength of 5mg. It comes in a package size of 30 capsules, and it is a prescription-only medication. The capsules contain Ramipril USP 5mg and should be stored at room temperature. It is important to keep out of reach of children and store in the original container. There is additional information about the manufacturer and repackaging.*
FDA Label Image

Figure 1. Kaplan-meier Estimates Of The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes In The Ramipril Group And The Placebo Group (Ramipril Fig1)

Figure 1. Kaplan-meier Estimates Of The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes In The Ramipril Group And The Placebo Group (Ramipril Fig1)
The text appears to be a graph or table showing the proportion of patients over time with the use of Ramipril medication. The values range from 0.0 to 0.2, with a significance level of P=0.0001. The x-axis shows the days of follow-up up to 1500 days, while the y-axis shows the proportion of patients.*
FDA Label Image

Figure 2. The Beneficial Effect Of Treatment With Ramipril On The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes Overall And In Various Subgroups (Ramipril Fig2)

Figure 2. The Beneficial Effect Of Treatment With Ramipril On The Composite Outcome Of Myocardial Infarction, Stroke, Or Death From Cardiovascular Causes Overall And In Various Subgroups (Ramipril Fig2)
This is a table related to different medical conditions and the number of patients that suffered from them. It also includes information about the incidence of composite outcomes in a placebo group and the relative risk in a Ramipril group. No further information is available.*
FDA Label Image

Chemical Structure (Ramipril Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.